The Psoriasis Glycome: Differential Expression of Cholesterol Particle Glycans and IgA Glycans Linked to Disease Severity.
The Psoriasis Glycome: Differential Expression of Cholesterol Particle Glycans and IgA Glycans Linked to Disease Severity.
复制标题
牛皮癣糖类：胆固醇颗粒聚糖和 IgA 聚糖的差异表达与疾病严重程度相关。
DOI：
10.1016/j.jid.2022.03.030
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
Maverakis,Emanual;Liakos,William;Park,Dayoung;Patel,Forum;Siddiqui,Fariha;Kailemia,MuchenaJ;Ruhaak,LRenee;Marusina,AlinaI;Luxardi,Guillaume;Gudjonsson,JohannE;Le,StephanieT;Armstrong,AprilW;Liao,Wilson;Merleev,AlexanderA;
Glycans are one of the four fundamental building blocks of life. Their small ionizable structures make them ideal targets for biomarker research and discovery. It has been hypothesized that each autoimmune disease will have a unique set of disease-associated glycan alterations and that the reversal of these alterations may ameliorate disease activity (Maverakis et al., 2015). To date, glycan alterations have been associated with many immune-mediated diseases (Maverakis et al., 2021; Parekh et al., 1985). Physiologic aging has also been associated with profound changes in the human glycome, and models based on these alterations can accurately predict biological age (Merleev et al., 2020). As a basis for future biomarker research and discovery efforts in psoriasis, in this study we characterize the psoriasis glycome. Specifically, we identify the glycan alterations associated with psoriasis, show that psoriasis treatment can partially reverse these alterations, and construct an IgA glycan regression model that correlates with psoriasis disease severity.Serum samples were collected from 25 patients with psoriasis and 25 age-and sex-matched healthy controls (Supplementary Figure S1). Of the 25 patients with psoriasis, 22 patients had samples taken at two time points: before treatment and week 12 after initiation of adalimumab, a TNF-blocking biologic medication used to treat psoriasis (Sivamani et al., 2013). For each patient, psoriasis severity was assessed using PASI, which was recorded at baseline and again at week 12. Glycan profiling (monitored analytes are shown in S upplementary Figures S2 and S3) was performed using the multiple reaction monitoring (MRM) mass spectrometry method (see Supplementary Materials and Methods), which has been highly validated and used in our previous studies (Hong et al., 2015; Li et al., 2019; Merleev et al., 2020; Park et al., 2018). Protein concentrations were determined on the basis of calibration curves, and glycopeptide relative responses were calculated using the area under the curve for the noted glycopeptide and a nonglycosylated reference peptide from the same protein, a method that normalizes the glycopeptide abundance to the abundance of the protein from which it was derived.
